Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The company enjoyed growth from key drivers including Vabysmo (faricimab), launched in 2022 for ophthalmology indications including wet age-related macular degeneration
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
2017, doi: 10.1016/S2213-8587(17)30013-X
Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare : Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations
Liu L, Chen J, Wang L, et al
Among the rest of the top five there was change, however, as Merck & Co climbed above Johnson & Johnson and AbbVie to take second place, and Novartis was replaced in fifth place by Roche
US$ 25.38
US$ 29.11
US$ 24.19
US$ 24.65
US$ 27.64
